Mark Cuban’s US Pharma Ventures: Ally Or Gadfly In The Mix For Indian Firms?
Mark Cuban’s newly launched online pharmacy and pharmacy benefit manager operation in the US has sparked interest in India. Can the billionaire entrepreneur’s venture punch above its weight and should Indian firms be watchful?
You may also be interested in...
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Mark Cuban’s generics venture has launched its online pharmacy in the US, highlighting in particular three products – imatinib, mesalamine and colchicine – that it says “epitomize the pharmacy’s striking savings.”
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.